ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

  • End date
    Jun 30, 2023
  • participants needed
  • sponsor
    Abivax S.A.
Updated on 20 February 2022
systemic therapy
measurable disease
antiviral therapy
local therapy
antiviral drugs


Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma


This is an open-label, uncontrolled phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma. The study consists of 2 phases, a Dose Escalation Phase and an Expansion Phase. Nivolumab will be administered, consistent with the US prescribing information, as a 30-minute IV infusion on Days 1 and 15 of each 28-Day cycle. ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day cycle (i.e., every 8 weeks).

Condition Carcinoma, Hepatocellular
Treatment ABX196
Clinical Study IdentifierNCT03897543
SponsorAbivax S.A.
Last Modified on20 February 2022


Yes No Not Sure

Inclusion Criteria

Men or women, Age 18 years
Patients with ECOG performance status 0 or 1
Patients with histologically confirmed diagnosis of HCC not amenable to curative surgery or local therapy
Patients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent
Patients with at least one prior systemic therapy for HCC
Patients eligible to be treated with nivolumab
Patients with measurable disease based on RECIST v1.1
Patients with Child-Pugh class A liver score within 7 days of first study dose
Patients with no history of hepatic encephalopathy
Patients with no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)
Patients with HBV infection must have received antiviral therapy for at least 12 weeks and HBV viral load must be documented to be <100 IU/mL within 7 days of first study dose
Patients with no active co-infection with HBV and HCV or HBV and HDV
Patients with no active drug or alcohol abuse

Exclusion Criteria

Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose
Patients with esophageal or gastric variceal bleeding within the past 6 months
Patients with portal vein invasion at the main portal (Vp4) or the inferior vena cava or cardiac involvement of HCC based on imaging
Patients with previous solid organ or hematologic transplantation
Patients with active autoimmune disease requiring systemic treatment in the past 2 years
Patients with diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days before first study dose
Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose
Patients with minor surgery to liver or another site within 1 week before first study dose
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note